Patents Examined by Changhwa J. Cheu
  • Patent number: 10317416
    Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 11, 2019
    Assignee: GAIA Medical Institute
    Inventor: Sarka O. Southern
  • Patent number: 10317321
    Abstract: The invention provides a method termed protein retention ExM (proExM), in which proteins, rather than labels, are anchored to the swellable gel, using a cross-linking molecule. This proExM strategy can be used to perform nanoscale imaging of immunostained cells and tissues as well as samples expressing various FPs as fluorescent signals from genetically encoded fluorescent proteins and/or conventional fluorescently labeled secondary antibodies and streptavidin that are directly anchored to the gel are preserved even when subjected to the nonspecific proteolytic digestion.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 11, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Paul Warren Tillberg, Fei Chen, Edward Stuart Boyden, Chih-Chieh Yu
  • Patent number: 10309970
    Abstract: Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ?0.07 as determined by their raw p-value or an average discriminatory p-value of ?0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: June 4, 2019
    Assignee: Biomerica, Inc.
    Inventors: Elisabeth Laderman, Zackary Irani-Cohen
  • Patent number: 10302654
    Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 28, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Tatiana Plavina, Paula S. Hochman, Michaela Lerner
  • Patent number: 10295544
    Abstract: This disclosure provides high throughput immunoblot methods and apparatus for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The method yields highly sensitive and accurate results and is useful in analyze complex system including an antigen from cell or tissue lysate.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: May 21, 2019
    Assignee: QUANTICISION DIAGNOSTICS INC.
    Inventor: Jiandi Zhang
  • Patent number: 10288614
    Abstract: A sample analysis device used to detect a level of exposure of organophosphorus within a sample comprising a sample collection pad, at least one conjugate zone comprising an anti-analyte antibody that is conjugated with a reporter label, and a control antibody that is conjugated with a reporter label, a blocking and/or test zone comprising an immobilized nanoparticle or other molecule that captures the Organophosphate-bound analyte, a second blocking and/or test zone comprising an immobilized antibody that binds to the unbound analyte and an optional third blocking and/or control zone comprising an immobilized antibody that binds to the control molecule wherein, when the analyte is bound by the Organophosphate in the sample it will bind to the first test line, and if the analyte is “free’ from the Organophosphate it will bind to the second test line, and the control antibody will bind to the control line.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: May 14, 2019
    Assignee: Countervail Corporation
    Inventors: G. William Basinger, Jr., Kristin H. Clement
  • Patent number: 10278624
    Abstract: A method for providing a assistance for maintaining or improving an individual's wellness, comprising the steps of measuring a presence and/or concentration of one or more biomarkers in a sample from the individual; predicting a wellness need for maintaining or improving the individual's wellness based on the measured presence and/or concentration of the one or more biomarkers, wherein the one or more biomarkers are indicators of the wellness need; and altering the living environment of the individual, providing a wellness product or service to the individual or providing information, guidance or advice to the individual for addressing the wellness need of the individual. A system providing assistance for maintaining or improving an individual's wellness is also provided.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: May 7, 2019
    Assignee: IPHENOTYPE LLC
    Inventors: Jay M. Short, Steve Briggs
  • Patent number: 10274486
    Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: April 30, 2019
    Assignee: Yale University
    Inventors: Rong Fan, Yao Lu, Jonathan Chen
  • Patent number: 10274498
    Abstract: This disclosure relates generally to detection and, in particular, to detecting objects within a sample or fraction thereof.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 30, 2019
    Assignee: RareCyte, Inc.
    Inventors: Daniel E. Campton, Arturo B. Ramirez, Melinda R. Duplessis
  • Patent number: 10267805
    Abstract: This disclosure relates generally to detection and, in particular, to detecting objects within a sample or fraction thereof.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 23, 2019
    Assignee: RareCyte, Inc.
    Inventors: Daniel E. Campton, Arturo B. Ramirez
  • Patent number: 10261101
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 16, 2019
    Assignee: ZORA BIOSCIENCES OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Patent number: 10261094
    Abstract: A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: April 16, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Manoj Rajadhyaksha, Michael Partridge, Albert Torri
  • Patent number: 10258667
    Abstract: The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Xinhua Yan, Anthony O. Caggiano
  • Patent number: 10254292
    Abstract: Methods are provided for estimating the relative amounts of identifiable compartments, such as different types of cells or cell components, within a biological sample. The methods use mass spectrometric analysis to quantitate compartment-specific molecules and thereby allow calculation of the amount of each compartment that is present in a biological sample. The methods can, for example, provide a measurement of hematocrit from a dried blood sample.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: April 9, 2019
    Assignee: SISCAPA ASSAY TECHNOLOGIES, INVC.
    Inventor: N. Leigh Anderson
  • Patent number: 10234455
    Abstract: Compositions and methods for diagnosing an increased risk of NPSLE are provided.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: March 19, 2019
    Assignee: The Research Foundation for State University of New York
    Inventors: Henri Tiedge, Anna Iacoangeli
  • Patent number: 10222371
    Abstract: A qualitative detection system and method for visual verification of the presence of human protein in a biopsy specimen collection bottle is disclosed. The system comprises a lateral flow assay assembly securely contained within the lid of a biopsy specimen collection bottle or secured at the bottom of the bottle. The lateral flow assay assembly comprises components that amplify in color intensity through a chromogenic reaction in the presence of certain proteins. A change in color of the components of the lateral flow assay assembly acts as a visual index to qualitatively confirm the placement of human tissue in the biopsy specimen collection bottle.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 5, 2019
    Assignee: Nano 2.0 Business Press, LLC
    Inventor: Steven M. Hacker
  • Patent number: 10209247
    Abstract: The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 19, 2019
    Assignee: BioVentures, LLC
    Inventors: Alan J. Tackett, Stephanie Byrum, Sean Taverna, Kevin Raney, Zachary Waldrip
  • Patent number: 10201812
    Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 12, 2019
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Eli N. Glezer, Sudeep Kumar, Pankaj Oberoi, George Sigal, Michael Tsionsky
  • Patent number: 10197579
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 5, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Gerald Scott Barden Horan, Ying Ye
  • Patent number: 10196672
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 5, 2019
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo